The majority of endocrine treatments of breast cancer act by reducing oestrogenic stimulation of the tumour cell. This can be achieved by (1) suppressing the supply of oestrogen to the tumour cell or (2) blocking oestrogen action at the cellular level by administration of oestrogen receptor antagonists such as tamoxifen.
The main pathway of oestrogen production in postmenopausal women is peripheral conversation of androstenedione into oestrone, which is called aromatisation because of conversion of the A-ring of the androgen to the aromatic Aring of oestrogens (Grodin et al., 1973) . In 1978 Santen and co-workers (Santen et al., 1978) demonstrated that this conversion could be inhibited by the drug aminoglutethimide in vivo. This finding introduced aromatase inhibition as a new therapeutic approach for postmenopausal breast cancer. Breast cancer patients treated with aminoglutethimide achieve response rates similar to that obtained with tamoxifen (L0nning & Kvinnsland, 1988) . However, as aminoglutethimide causes several side effects, much effort is currently being spent on the development of alternative aromatase inhibitors for clinical use (L0nning et al., 1990) .
CGS 16949A (Ciba-Geigy Pharmaceuticals) is a potent new aromatase inhibitor which causes regression of DMBAinduced mammary tumours in rats (Schieweck et al., 1988) and has now been investigated in phase I clinical trials (Lipton et al., 1990; Stein et al., 1990) . In vitro studies have shown this drug to inhibit aromatisation at drug concentrations 200-400 fold lower than the concentration of aminoglutethimide needed to produce the same effect (Steele et al., 1987) . Recent investigations reported plasma and urine oestrogens to be suppressed in patients treated with CGS 16949A, but there is disagreement about the dose relationship (Santen et al., 1989; Dowsett et al., 1990; Klepp et al., 1990) .
Although suppression of plasma oestrogen levels may be the determinant of the tumour response it is important to recognise that changes in these levels cannot indicate whether it is synthesis or metabolic clearance of the oestrogen(s) or a combination of the two which is affected. For example, recent results suggest enhancement of oestrogen metabolism could be partly responsible for the suppression of plasma oestrogen levels by aminoglutethimide (L0nning et al., 1987; L0nning et al., 1989b tracers were dissolved in a total volume of 54 ml of saline:ethanol (92:8 w/w). Due to a high ratio between 3H and "C DPM in the injection vehicle, this was prepared and the amount of tracer measured according to a strict protocol to avoid misreading of 3H in the "'C channel during the measurement of isotope ratios: 5 tCi of [4-'4C]E, in 3.5 ml of ethanol was added to 50 ml of saline. From this solution four aliquots of 50 fil each were obtained for estimation of the '4C in the injection mixture by liquid scintillation counting.
[6,7-3H]A was added in 0.5 ml of ethanol, and another four 50 jlI aliquots of the solution were obtained for estimation of the 3H component of the injection mixture. Fifty ml of this solution was aspirated into a glass syringe, and administered as a 10 min i.v. bolus injection through a teflon cannula. Urine was collected for 4 days after injection. The sample was mixed, its total volume measured, and two aliquots of 800 ml each frozen and stored at -20°C until analysis. Urine analysis A detailed description of the analytical method and its reproducibility is given elsewhere (Jacobs et al., 1990) . Briefly, the analysis is conducted as follows: Urine samples (800 ml) were thawed and the steroid glucuronides concentrated by use of Sep-Pak C18 cartridges followed by chromatography on a DEAE Sephadex column eluted by a salt gradient. The salts were eliminated by further chromatography on C18 Sep-Pak columns. Hydrolysis was performed at 37°C for 48 h with 1 ml (144,000 units) Pglucuronidase (Sigma, G-8885). Following extraction, the hydrolysed oestrogens were separated from androgens by a two-step anion exchange chromatography process using DEAE-Sephadex. Thereafter, oestrone (E,), oestradiol (E2) and oestriol (E3) were isolated by HPLC using a Hypersil ODS 5 1t (Chrompack) 4.6 x 250 mm column and a mobile phase of acetonitrile/phosphate buffer 0.05 M pH 3 (L0nning et al., 1989c; Jacobs et al., 1990 ). Due to the high level of 3H-labelled androgens in the urine it was not possible to measure the recovery of oestrogen metabolites during these analytical steps. However, since between 50 and 70% of "C-labelled oestrogens administered are recovered in a 72-96 h urine sample (Fishman et al., 1966; Zumoff et al., 1968) , the overall recovery may be estimated as about 35-50%.
Liquid scintillation counting All samples were counted in a Tricarb 1990CA liquid scintillation counter using automatic quench calibration. Each sample was counted in a 10 ml plastic vial with Emulsifier Safe (Packard) scintillation fluid. Under these conditions, the computer program caused between 0.2 and 0.4% of 3H to be read in the 14C channel but no 14C in the 3H channel.
When repeat analyses were conducted on samples obtained in control and on-treatment situations, interassay coefficients of variation for all three metabolites were found to be less than 5% (Jacobs et al., 1991 ). An example of samples subjected to repeat analysis from one patient (No. 2) from both control and on-treatment situations is given in Table I . the separated oestrogens is clear. Lack of radioactivity in the area of the chromatogram corresponding to catechol oestrogens (between E2 and El) suggests that these metabolites have probably been destroyed during the analytical process because no antioxidants were used (L0nning et al., 1989c) . The inclusion of an antioxidant such as ascorbic acid would have interfered with the anion exchange chromatography prior to HPLC.
Aromatisation of A to El in the eight patients before commencing on CGS 16949A treatment is shown in Figure 3 . The percentage of aromatisation is obtained separately from the isotope ratio in the E,, E2 and E3 fraction. It can be seen that there is a relatively close agreement between the results obtained from the different oestrogen metabolites for each patient.
The isotope ratio could be determined in both the El and E3 fractions in the treatment as well as the control situation in all patients. However, while the isotope ratio in the E2 fraction could be determined in all patients in the control % aromatisation Figure 4 Per cent aromatase inhibition (mean value for the oestrone and oestriol fraction) compared to initial aromatisation value (mean value for all three oestrogen metabolites).
Discussion
The method used in this investigation provides a reliable method to measure peripheral aromatisation in vivo, with intra-and inter-assay coefficients of variation of less than 5% (Jacobs et al., 1991) . In addition, it provides several advantages compared to other alternative methods.
Firstly, plasma oestrogen levels may vary during the day (Vermeulen et al., 1976; L0nning et al., 1989a) , which could be related to a time-related variation in aromatisation. Measuring aromatisation in 4-day collections of urine gives a mean value of aromatisation over time which avoids any possible short time influences.
Secondly, plasma tracer studies require a sufficient infusion time to achieve steady state plasma levels. Plasma El needs to equilibrate with the EIS pool (L0nning et al., 1989b) . EIS has a slow half-life (about 6 h) and a plasma clearance value of about 3-7 1 h-' only (Longcope, 1972; Ruder et al., 1972; L0nning et al., 1987) . Thus, it may be difficult to reach a plasma steady state condition for an El tracer without performing long-term infusions. This problem seems to be of particular importance in obese patients who seem to have a slower turnover of their oestrogen pool (Longcope, 1982) . A third problem relates to method sensitivity. In contrast to E1S, El has a rapid clearance rate about 50-801 h-' (Longcope & Williams, 1974; L0nning et al., 1989b only, but it would most probably be detected in a urinary assay measuring the isotope ratio in different metabolites. Following tracer oestrogen injections urinary radioactivity is excreted over the next 3 to 4 days (L0nning et al., 1987; L0nning & Skulstad, 1989) . Thus any minor loss of urine during the sampling period would be expected to have little impact on the result obtained, in as much as we measured the isotope ratio and not the total amount of the excreted metabolites. The isotope ratio was not measured in unconjugated oestrogens or sulphated metabolites since about 90% of total urinary oestrogen metabolites are excreted as glucuronide conjugates (Gurpide, 1978) .
It was not possible to isolate catechol oestrogens by this method. Production of catechol oestrogens (mainly 20H-E1) and E3 are the two major hydroxylation pathways in oestrogen metabolism, and these pathways are considered to be substrate competitive (Bolt, 1979) . Accordingly, any change in the urinary excretion of the one metabolite would be expected to result in alterations in the other metabolite. A consistent isotope ratio in the E3 and El fractions therefore suggests a consistent ratio between El and the other major metabolites in general.
Several investigations have confirmed that CGS 16949A causes oestrogen suppression in postmenopausal breast cancer patients Santen et al., 1989; Klepp et al., 1990) , but the results differ somewhat according to which dose of drug was found to be the lowest necessary to obtain maximal oestrogen suppression. Santen et al. (1989) found a drug schedule of 1 mg b.d. to give maximum suppression, whilst Dowsett et al. (1990) reported that plasma oestradiol levels were suppressed further when the CGS 16949A dose was escalated from 1 mg b.d. to 2 mg b.d. The classical aromatase inhibitor, aminoglutethimide, was an unspecific drug, inhibiting several adrenal hydroxylases in addition to its influence on the aromatase enzyme (Harris et al., 1983; Vermeulen et al., 1983) . CGS 16949A was synthesised in an attempt to develop a pure aromatase inhibitor. However, recent results suggest that 16949A inhibits adrenal secretion of aldosterone in a dose-dependent manner in the 1-2 mg b.d. dose range . Thus, it may be of clinical importance to determine the minimal drug dose necessary to achieve optimal aromatase inhibition.
The results of this study show that some patients may have a less effective inhibition of aromatase with 1 mg b.d. than with 2 mg b.d. When given at this higher dose, CGS 16949A caused aromatase inhibition comparable to that previously reported for aminoglutethimide (Santen et al., 1978; Dowsett et al., 1985) and 4-hydroxyandrostenedione (Reed et al., 1990) . Thus, the results of this investigation illustrate the importance of tracer studies to evaluate aromatase inhibitors. Firstly, it confirms that the drug acts as an aromatase inhibitor in vivo. Secondly, this method proves to be a valuable aid to discriminate between the effectiveness of different doses of an aromatase inhibitor.
As plasma drug levels for CGS 16949A were not available, it was not possible in this report to assess whether the variation in aromatase inhibition for the patients treated with CGS 16949A could be due to variations in plasma drug levels or variation in drug sensitivity. Most patients treated with a CGS 16949A drug schedule of 2 mg b.d. will have steady state plasma drugs concentrations varying between 2 and lO ng ml-' or 8 and 40 nM (Lipton et al., 1990) . Steady state plasma concentrations of aminoglutethimide in patients receiving 250 mg or 1000 mg daily are about 400 and 1600-fold higher respectively (Murray et al., 1979; L0nning et al., 1985; Stuart-Harris et al., 1985) . While in vitro studies have suggested CGS 16949A to be 200 and 400 times more potent than aminoglutethimide (Steele et'al., 1987) , any comparison of plasma drug levels should be interpreted with care, as no information considering tissue drug levels are available.
In conclusion, our results indicate that CGS 16949A given as a drug schedule of 1 mg b.d. caused submaximal aromatase inhibition in many patients, while the dose of 2 mg b.d. caused more than 90% aromatase inhibition in each of the three patients investigated. Together with the clinical results from phase II trials, this result should provide the basis for selecting the appropriate dose of CGS 16949A if the drug is to be considered for phase III comparative trials with established agents. The measurement of aromatase inhibition in vivo is likely to become a benchmark in comparative studies of aromatase inhibitors. It is important that a sufficiently sensitive and rugged method such as that described is used to make the measurements.
